Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear.
It was a relatively quiet news day. I was not sure there would be much to write about and there is nothing really new or compelling. There are some quick.
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers.
Generally a mixed day in biotech land today with some interesting stock specific moves but nothing really dramatic in terms of news. Looks like a quiet end to the week.
This is both an early and short report for today as I am on sick child duty for the day. Luckily it was not a particularly newsy morning and if.
The SGMO ICAAC abstracts are now available. This links to the late breaker abstract. Abstract: Background: Expression of CCR5 by CD4 cells is necessary for productive R5 HIV infection. Biallelic.
Decent day in the market but biotechs did not seem to participate to the same extent. Of course, I do not have much time to follow the market on Tuesday.
Some interesting news today and generally a positive market environment, although some of the recent high fliers seemed to take most of the day off. That is not completely surprising.